Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Internal Medicine Journal|March 1, 2019
Evaluating a risk assessment tool to improve triaging of patients to colonoscopiesThomas M Elliott, Anton Lord, Lisa A Simms, et al.
Digestive Diseases and Sciences|September 20, 2022
A Method Using Longitudinal Laboratory Data to Predict Future Intestinal Complication in Patients with Crohn's DiseaseJames Irwin, Anton Lord, Emma Ferguson, et al.
Iscience|December 9, 2019
Co-existence of Network Architectures Supporting the Human Gut MicrobiomeCaitlin V Hall, Anton Lord, Richard Betzel, et al.
Free Radical Biology & Medicine|November 27, 2013
Selenoprotein S is a marker but not a regulator of endoplasmic reticulum stress in intestinal epithelial cellsBodo Speckmann, Kirsten Gerloff, Lisa Simms, et al.
Alimentary Pharmacology & Therapeutics|November 27, 2019
A validated risk stratification tool for detecting high-risk small bowel Crohn's diseaseEddie X Shen, Anton Lord, James D Doecke, et al.
Digestive Diseases and Sciences|November 28, 2018
Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's DiseaseJames R Irwin, Emma Ferguson, Lisa A Simms, et al.
Journal of Gastroenterology and Hepatology|June 15, 2007
Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's diseasePeter R Gibson, Adèle R Weston, Amelia Shann, et al.
Clinical & Translational Immunology|August 2, 2019
Crohn's disease is facilitated by a disturbance of programmed death-1 ligand 2 on blood dendritic cellsRebecca Faleiro, Ji Liu, Deshapriya Karunarathne, et al.
World Journal of Gastroenterology|November 30, 2016
Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapyAngela C Baird, Dominic Mallon, Graham Radford-Smith, et al.
Rheumatology and Therapy|August 27, 2021
Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin PsoriasisSteven L Truong, Jasmine Chin, David F L Liew, et al.
Pageof 7